Patents by Inventor Kai Schiemann

Kai Schiemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS
    Publication number: 20230203034
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in Claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: March 1, 2023
    Publication date: June 29, 2023
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
    Patent number: 11608338
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: March 21, 2023
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20220306588
    Abstract: The invention relates to benzimidazole derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: March 14, 2022
    Publication date: September 29, 2022
    Applicant: Merck Patent GmbH
    Inventors: Eva-Maria TANZER, Kai SCHIEMANN, Markus KLEIN
  • Benzimidazole derivatives as adenosine receptor antagonists
    Patent number: 11453647
    Abstract: The invention relates to benzimidazole derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: September 27, 2022
    Assignee: Merck Patent GmbH
    Inventors: Eva-Maria Tanzer, Kai Schiemann, Markus Klein
  • THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20220119412
    Abstract: The invention relates to thiazolopyridine derivatives which fall under the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: January 21, 2020
    Publication date: April 21, 2022
    Applicant: Merck Patent GmbH
    Inventors: Eva-Maria TANZER, Kai SCHIEMANN, Alejandro CRESPO
  • Quinoxaline derivatives as adenosine receptor antagonists
    Patent number: 11192899
    Abstract: The invention relates to quinoxaline derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: December 7, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Eva-Maria Tanzer, Kai Schiemann, Markus Klein
  • Thiazolopyridine derivatives as adenosine receptor antagonists
    Patent number: 11186592
    Abstract: The invention relates to thiazolopyridine derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: November 30, 2021
    Assignee: Merck Patent GmbH
    Inventors: Eva-Maria Tanzer, Kai Schiemann, Markus Klein
  • IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS
    Publication number: 20210198257
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 1, 2021
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
    Patent number: 10975075
    Abstract: The compounds are imidazolonylquinoline compounds of the following formula and are useful in the inhibition, regulation and/or modulation of signal transduction by kinases, in particular ATM kinase, furthermore for the treatment of diseases which relate to ATM kinase, in particular cancer, and which compounds can be supplied in pharmaceutical compositions and kits.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: April 13, 2021
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20200354375
    Abstract: The invention relates to quinoxaline derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: August 20, 2018
    Publication date: November 12, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Eva-Maria TANZER, Kai SCHIEMANN, Markus KLEIN
  • IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS
    Publication number: 20200325137
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 15, 2020
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
    Patent number: 10745399
    Abstract: A compound of formula (IV) or a pharmaceutically acceptable salt, solvate, tautomer or stereoisomer thereof These imidazolonylquinoline compounds are useful in the inhibition, regulation and/or modulation of signal transduction by kinases, in particular ATM kinase, furthermore in pharmaceutical compositions, and in their use for the treatment of diseases which relate to ATM kinase, in particular cancer.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20200207720
    Abstract: The invention relates to benzimidazole derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: August 20, 2018
    Publication date: July 2, 2020
    Applicant: Merck Patent GmbH
    Inventors: Eva-Maria TANZER, Kai SCHIEMANN, Markus KLEIN
  • THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20200181171
    Abstract: The invention relates to thiazolopyridine derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Application
    Filed: July 2, 2018
    Publication date: June 11, 2020
    Applicant: MERCK PATENT GMBH
    Inventors: Eva-Maria TANZER, Kai SCHIEMANN, Markus KLEIN
  • Imidazolonylquinolines and the use thereof as ATM kinase inhibitors
    Patent number: 10457677
    Abstract: Compounds of the formula (I), which are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: October 29, 2019
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Kai Schiemann
  • IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS
    Publication number: 20190211013
    Abstract: Compounds of the formula (I), in which R1, R3, Het1 and HET have the meanings given in Claim 1, are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 11, 2019
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • Pyridyl piperidines
    Patent number: 9926319
    Abstract: The invention provides novel substituted pyridyl piperidine compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: March 27, 2018
    Assignees: MERCK PATENT GMBH, Cancer Research Technology Limited
    Inventors: Kai Schiemann, Frank Stieber, Michel Calderini, Julian Blagg, Aurelie Mallinger, Dennis Waalboer, Christian Rink, Simon Ross Crumpler
  • IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS
    Publication number: 20180072715
    Abstract: Compounds of the formula (I), which are ATM kinase inhibitors and can be employed, inter alia, for the treatment of cancer.
    Type: Application
    Filed: March 31, 2016
    Publication date: March 15, 2018
    Applicant: Merck Patent GmbH
    Inventors: Thomas FUCHSS, Kai SCHIEMANN
  • Indazoles
    Patent number: 9862717
    Abstract: The invention provides novel substituted indazole compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: January 9, 2018
    Assignees: Merck Patent GmbH, Cancer Research Technology Limited
    Inventors: Kai Schiemann, Aurelie Mallinger
  • 2-aminopyridine compounds
    Patent number: 9834541
    Abstract: The invention provides novel substituted 2-aminopyridine compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: December 5, 2017
    Assignees: CANCER RESEARCH TECHNOLOGY LIMITED, MERCK PATENT GMBH
    Inventors: Kai Schiemann, Frank Stieber, Julian Blagg, Aurelie Mallinger, Dennis Waalboer, Christian Rink, Simon Ross Crumpler